Dilated choroidal veins and their role in recurrences of myopic macular neovascularisations.

Autor:	Xie S; Department of Ophthalmology and Visual Science, Tokyo Medical and Dental University, Bunkyo-ku, Japan., Du R; Department of Ophthalmology and Visual Science, Tokyo Medical and Dental University, Bunkyo-ku, Japan., Fang Y; Department of Ophthalmology and Visual Science, Tokyo Medical and Dental University, Bunkyo-ku, Japan.; Beijing Ley Laboratory of Ophthalmology and Visual Science, Beijing Tongren Eye Center, Beijing, China., Onishi Y; Department of Ophthalmology and Visual Science, Tokyo Medical and Dental University, Bunkyo-ku, Japan., Igarashi T; Department of Ophthalmology and Visual Science, Tokyo Medical and Dental University, Bunkyo-ku, Japan., Takahashi H; Department of Ophthalmology and Visual Science, Tokyo Medical and Dental University, Bunkyo-ku, Japan., Kamoi K; Department of Ophthalmology and Visual Science, Tokyo Medical and Dental University, Bunkyo-ku, Japan., Ohno-Matsui K; Department of Ophthalmology and Visual Science, Tokyo Medical and Dental University, Bunkyo-ku, Japan k.ohno.oph@tmd.ac.jp.
Jazyk:	angličtina
Zdroj:	The British journal of ophthalmology [Br J Ophthalmol] 2022 Oct; Vol. 106 (10), pp. 1429-1435. Date of Electronic Publication: 2021 Apr 28.
DOI:	10.1136/bjophthalmol-2021-318970
Abstrakt:	Aim: To determine whether there is a correlation between the presence of macular dilated choroidal vein (DCV) and the recurrence of myopic macular neovascularisation (MNV) after antivascular endothelial growth factor (VEGF) treatment. Methods: Medical records of 168 eyes of 163 patients with myopic MNV were reviewed for the presence of macular DCV and episodes of recurrences. A macular DCV was defined as a choroidal vein whose diameter was 2× larger than the adjacent veins coursing in the macular area of 5.5 mm diameter. Results: Macular DCV existed in 47 (28%) of the eyes with myopic MNV. 70 eyes (41.7%) had recurrence during a mean follow-up period of 52.5±23.0 months. Recurrence was found in 28 of the 47 eyes (59.6%) with DCV, which was significantly more frequent than the 42 of the 121 eyes (34.7%) without DCV (p=0.003). Cox model analysis showed that macular DCV was an independent risk factor (HR: 2.0, 95% CI 1.1 to 3.5) for recurrence. The recurrence rate was significantly higher in eyes with DCV within the first 2 years after the onset than in eyes without DCV. Conclusions: Macular DCVs may be indicators of a more aggressive phenotype of eyes with myopic MNV. These eyes need careful monitoring after anti-VEGF therapies. Competing Interests: Competing interests: None declared. (© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu